Chronic Obstructive Pulmonary Disease | Treatment Algorithms | Claims Data Analysis | US | 2017
The COPD treatment algorithm continues to evolve, with changing recommendations on the use of ICS s, LABA / ICS FDC s, and LABA / LAMA FDC s. This study reveals which therapies are prescribed first-line after diagnosis and how treatment evolves as patients move through additional lines of therapy. Both short-acting therapies and long-acting therapies are included, and many patients receive both rescue and maintenance therapies. Additionally, some patients receive a combination of a LAMA and a LABA / ICS FDC , and LABA / LAMA FDC s are beginning to gain traction in this.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
